ArticleCancer immunology research2016
ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
Article in Cancer immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions.Frontiers in oncology · 2025Review
- Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy.The Journal of experimental medicine · 2024Article
- CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.Cancer discovery · 2023Article
- Cutting-Edge CAR Engineering: Beyond T Cells.Biomedicines · 2022Review
- Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects.Nature nanotechnology · 2021Article
- Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells.Bioengineered · 2021Article
- Strategies targeting FLT3 beyond the kinase inhibitors.Pharmacology & therapeutics · 2021Review
- Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.Cancer science · 2021Review
- [Structural evolution and prospect of chimeric antigen receptor T cell (CAR-T cell)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.JAMA oncology · 2020Review
- Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly.International journal of molecular sciences · 2020Article
- CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.Frontiers in immunology · 2019Review
- Nanobody Based Dual Specific CARs.International journal of molecular sciences · 2018Article
- Therapeutic T cell engineering.Nature · 2017Review
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.